Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis

Peter Waddingham, Nicholas Simmonds, Diana Bilton
European Respiratory Journal 2014 44: P1969; DOI:
Peter Waddingham
1Cystic Fibrosis Centre, Royal Brompton Hospital, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Simmonds
1Cystic Fibrosis Centre, Royal Brompton Hospital, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Bilton
1Cystic Fibrosis Centre, Royal Brompton Hospital, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Intravenous aminophylline (IVA) is sometimes used in the treatment of pulmonary exacerbations of cystic fibrosis (CF), however there is limited evidence for its benefit and small scale data suggest higher dosing may be needed for therapeutic effects (Isles et al 1983). We aimed to assess the safety, tolerability and efficacy of IVA in our large adult CF centre.

Methods: Retrospective pilot study of consecutive patient admissions receiving IVA over 5 months (Oct 2013-Feb 2014) including assessment of dose prescribed, serum levels, and side effects; with an observational subgroup analysis of efficacy (spirometry pre/post IVA and sputum clearance) in 15 patients prospectively.

Results: 30 patients received IVA. Median (range) duration of treatment was 8 (3-16) days. All infusions commenced at ≥0.5mg/kg/hour. Of 240 serum levels: 59.6% were sub therapeutic, 40% therapeutic (10-20mg/L) and 0.4% high. Side effects were common (60%) but did not lead to drug cessation (n=0).

% Predicted FEV1 and FVC improved from median (range) 33 (17-52) to 41 (22-63) and 49 (20-85) to 69 (29-108), respectively. Median change in % predicted of FEV1 7.5 (0-16) and FVC 12.5 (0-59). Improved sputum clearance was reported in 67% (n=10) of patients. 80% (n=12) of patients had therapeutic levels, not clearly linked to sputum clearance or improved spirometry.

Conclusion: High doses are required to achieve therapeutic levels in most patients although toxicity is extremely rare. Side effects are common but tolerance to these is high. Efficacy data suggests potential benefit with IVA regardless of serum levels; this now needs to be tested in a prospective controlled study.

  • Cystic fibrosis
  • Bronchodilators
  • Infections
  • © 2014 ERS
Previous
Back to top
Vol 44 Issue Suppl 58 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
Peter Waddingham, Nicholas Simmonds, Diana Bilton
European Respiratory Journal Sep 2014, 44 (Suppl 58) P1969;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
Peter Waddingham, Nicholas Simmonds, Diana Bilton
European Respiratory Journal Sep 2014, 44 (Suppl 58) P1969;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Human neutrophils release bioactive inflammasome complexes; relevance for cystic fibrosis
  • Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis
  • Infant lung function testing: First in vivo report of a novel inert gas washout method to measure LCI
Show more 7.3 Cystic Fibrosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society